Virogenics
Organisation
People
Sources: reporter.nih.gov
Grants and prizes
U01, Long-term, non-clinical toxicology for advancing CMS121 to Phase 2 trials for AD, U01AG084549, US$1.3m, 2024–2027, 12 Aug 2026
R44, Paving the Way to Phase 2 Trials of CMS121 for Alzheimer's Disease, R44AG085775, US$2.4m, 2024–2025, 26 Sept 2024
Sources: reporter.nih.gov